TScan Therapeutics (TCRX)
NASDAQ:TCRX
Want to see TCRX full AI Analyst Report?
TCRX Stock Chart & Stats
$1.19
-$0.17(-5.65%)
At close: 4:00 PM EST
$1.19
-$0.17(-5.65%)
Day’s Range― - ―
52-Week Range$0.85 - $2.57
Previous CloseN/A
Volume150.47K
Average Volume (3M)476.93K
Market Cap
$60.12M
Enterprise Value$19.44M
Total Cash (Recent Filing)$128.06M
Total Debt (Recent Filing)$92.54M
Price to Earnings (P/E)―
Beta1.97
Next Earnings
Aug 19, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.96
Shares Outstanding61,074,230
10 Day Avg. Volume455,904
30 Day Avg. Volume476,927
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.05
Price to Sales (P/S)12.58
P/FCF Ratio-0.93
Enterprise Value/Market Cap0.32
Enterprise Value/Revenue2.13
Enterprise Value/Gross Profit2.30
Enterprise Value/Ebitda-0.16
Forecast
1Y Price Target
$6.00Price Target Upside404.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1.02
Revenue Forecast (FY)$7.56M
Bulls Say, Bears Say
Bulls Say
High Gross MarginVery high gross margins (~92%) indicate a structurally low direct cost base for productized outputs. For a platform-focused biotech, durable high margins support strong operating leverage as collaboration or product revenues scale, improving long-term path to profitability once commercialization begins.
Manageable LeverageReported debt-to-equity near 0.62 and positive equity provide some financial flexibility for a clinical-stage company. Manageable leverage reduces near-term solvency risk and allows continued R&D execution while pursuing financing, which is important given the lengthy development timelines in cell therapy.
Proprietary TCR PlatformA focused platform for identifying disease-specific TCR targets and engineering T cells creates durable competitive advantages: a pipeline of program candidates, licensing and partnership potential, and the possibility to address multiple indications, which diversifies long-term revenue pathways beyond single assets.
Bears Say
Heavy Cash BurnSustained operating cash outflows (~-$122M) and free cash flow (~-$125M) indicate ongoing high cash consumption. This structural burn requires recurrent external financing, limits strategic optionality, and raises the risk of program delays or reprioritization absent new capital, affecting multi‑quarter resilience.
Large Ongoing LossesVery large trailing net losses (~$124M) show operating costs far exceed current revenues. Persistent negative profitability erodes equity, depresses returns, and makes the company dependent on financing; without material revenue from partners or successful programs, losses threaten long-term sustainability.
Dilution Risk From Authorized Shares IncreaseDoubling authorized shares structurally raises the company’s capacity to issue equity. For a cash‑hungry biotech, this increases the likelihood of sizable future share issuances to fund operations, creating a durable dilution pathway that can materially alter capital structure and shareholder value over time.
TScan Therapeutics News
TCRX FAQ
What was TScan Therapeutics’s price range in the past 12 months?
TScan Therapeutics lowest stock price was $0.85 and its highest was $2.57 in the past 12 months.
What is TScan Therapeutics’s market cap?
TScan Therapeutics’s market cap is $60.12M.
When is TScan Therapeutics’s upcoming earnings report date?
TScan Therapeutics’s upcoming earnings report date is Aug 19, 2026 which is in 60 days.
How were TScan Therapeutics’s earnings last quarter?
TScan Therapeutics released its earnings results on May 06, 2026. The company reported -$0.22 earnings per share for the quarter, missing the consensus estimate of -$0.202 by -$0.018.
Is TScan Therapeutics overvalued?
According to Wall Street analysts TScan Therapeutics’s price is currently Undervalued.
Does TScan Therapeutics pay dividends?
TScan Therapeutics does not currently pay dividends.
What is TScan Therapeutics’s EPS estimate?
TScan Therapeutics’s EPS estimate is -0.26.
How many shares outstanding does TScan Therapeutics have?
TScan Therapeutics has 61,074,230 shares outstanding.
What happened to TScan Therapeutics’s price movement after its last earnings report?
TScan Therapeutics reported an EPS of -$0.22 in its last earnings report, missing expectations of -$0.202. Following the earnings report the stock price went up 3.306%.
Which hedge fund is a major shareholder of TScan Therapeutics?
Currently, no hedge funds are holding shares in TCRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TScan Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.00 (404.20% Upside)
$6.00 (404.20% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.2%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.14%
12-Months-Change
Fundamentals
Return on Equity
-91.94%
Trailing 12-Months
Asset Growth
-39.29%
Trailing 12-Months
Company Description
TScan Therapeutics
TScan Therapeutics, Inc. is a biopharmaceutical enterprise, currently in its preclinical development stage, focused on engineering T cell receptor (TCR) therapies to combat various cancers. The company's pipeline features programs like TSC-100 and TSC-101, which are engineered to address blood cancers by clearing remnant leukemia cells and averting disease recurrence following hematopoietic stem cell transplantation. Additionally, TScan is advancing multiple candidates, including TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204, targeting solid tumor indications. Beyond its oncology efforts, the company is also engaged in vaccine development for infectious agents, such as SARS-CoV-2. TScan has formed a strategic collaboration and licensing arrangement with Novartis Institutes for BioMedical Research, Inc., aimed at pinpointing novel cancer-specific antigens derived from the T cells of particular cancer patients. Founded in 2018, TScan Therapeutics, Inc. operates from its headquarters in Waltham, Massachusetts.
TCRX Stock 12 Month Forecast
Average Price Target
$6.00
▲(404.20% Upside)
Technical Analysis
Zentalis Pharmaceuticals
―
ALX Oncology Holdings
―
Inhibikase Therapeutics
―
Surrozen
―
Instil Bio
―
Ownership Overview
17.47% Insiders
5.44% Mutual Funds
32.09% Other Institutional Investors
41.41% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---